Dr David Gilham | Vice President of Research and Development

Dr David Gilham, Vice President of Research and Development, Celyad

Dr. David Gilham first joined Celyad in April 2016 as member of the Scientific Advisory Board. As from September 1st, 2016, David became Vice-President R&D, heading the implementation of our Research and Development strategy for our programs in immuno-oncology. Dr. Gilham received his Ph.D in Molecular Pharmacology at the University of Dundee prior to moving to Bristol University in 1996 to work on CAR T cells with Professor Robert Hawkins. The group moved to Manchester in 1998 where his research activity has focused on engineering T-cells for cancer therapy and developing the necessary pre-clinical studies to support translation of this therapy into phase I/II clinical trials in Manchester. Prior to joining Celyad, David was a Reader in the Institute of Cancer Sciences, University of Manchester, UK and led the Clinical and Experimental Immunotherapy Group based within the Manchester Cancer Research Centre   


Advanced Therapies and Regenerative Medicine Day 1 - Wednesday 16th May 2018 @ 14:30

Panel Discussion: How can clinical challenges be overcome to enable CAR-T and immunotherapy to help more patients?

Advanced Therapies and Regenerative Medicine Day 1 - Wednesday 16th May 2018 @ 15:10

Exploiting NK receptors for CAR T cell therapy of cancer

  • The NK cell receptor NKG2D can be effectively engineered as a CAR to provide T cells with ‘NK’ specificity
  • Current clinical testing of the NKG2D CAR (CYAD-01) involves targeting solid and haematological malignancy to examine the potency of the approach

back to speakers

World Advanced Therapies & Regenerative Medicine Congress


Erica Baeta
+44 (0)207 092 1152


Jessica Robinson
t/ +44 (0)207 092 1150


Issa Mauthoor
+44 (0)207 092 1257